• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Regeneron Pharmaceuticals

eyeball retinal diseases
Biotech

Unity's stock tumbles after eye treatment fails to match Eylea

Unity’s eye treatment failed to match Eylea at 20 weeks—the only time stamp in which the candidate was inferior to Regeneron’s blockbuster.
Gabrielle Masson Mar 24, 2025 11:11am
childrens art

Regeneron gene therapy restores hearing in 10 of 11 children

Feb 24, 2025 3:00pm
A graphic representation of a DNA sequence

JPM25: Regeneron, Illumina back Truveta to sequence 10M genomes

Jan 13, 2025 10:12am
graphic of a larger shark chomping up a smaller one

Regeneron snaps up eye biotech, snaring science but not staff

Jan 2, 2025 3:58pm
Graphic of a drop of blood made up of small data points and nodes

Regeneron anticoagulant bests enoxaparin, matches Eliquis

Dec 19, 2024 8:50am
gas burners cooking

ESMO: Regeneron's Opdualag rival shows 57% response rate

Sep 14, 2024 3:00am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings